In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α1A Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia
Authors:
- 1 July 2000
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 43 (14) , 2703-2718
Abstract
α1 Adrenergic receptors mediate both vascular and lower urinary tract tone, and α1 receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the α1A receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective α1A receptor subtype antagonists. In receptor binding assays, these types of compounds generally display Ki values for the α1a receptor subtype 1b and α1d receptor subtypes. Many of these compounds were also evaluated in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure without significantly affecting blood pressure. While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the α1a over the α1b and α1d receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.Keywords
This publication has 12 references indexed in Scilit:
- Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 2. Approaches To Eliminate Opioid Agonist Metabolites via Modification of Linker and 4-Methoxycarbonyl-4-phenylpiperidine MoietyJournal of Medicinal Chemistry, 1999
- Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 1. Structure−Activity Relationship in DihydropyrimidinonesJournal of Medicinal Chemistry, 1999
- Design and Synthesis of Novel α1a Adrenoceptor-Selective Antagonists. 3. Approaches To Eliminate Opioid Agonist Metabolites by Using Substituted Phenylpiperazine Side ChainsJournal of Medicinal Chemistry, 1999
- Expedient synthesis of 5-unsubstituted 3,4-dihydropyrimidin-2(1H)-onesTetrahedron Letters, 1998
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- Synthesis and in Vitro Characterization of N-[5-(4,5-Dihydro-1H-imidazol-2-yl)- 2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulfonamide and Its Enantiomers: A Novel Selective α1A Receptor AgonistJournal of Medicinal Chemistry, 1996
- Discovery of .alpha.1a-Adrenergic Receptor Antagonists Based on the L-Type Ca2+ Channel Antagonist NiguldipineJournal of Medicinal Chemistry, 1995
- Use of an α1-Blocker, YM617, in the Treatment of Benign Prostatic HypertrophyJournal of Urology, 1990
- Dihydropyrimidine calcium channel blockers: 2-heterosubstituted 4-aryl-1,4-dihydro-6-methyl-5-pyrimidinecarboxylic acid esters as potent mimics of dihydropyridinesJournal of Medicinal Chemistry, 1990
- The Development of Human Benign Prostatic Hyperplasia with AgeJournal of Urology, 1984